Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business ...( FREMONT Calif. March 4 /- Vermill...)

FREMONT, Calif., March 4 /PRNewswire-FirstCall/ -- Vermillion, Inc. (Nasdaq: VRMLD), a molecular diagnostics company, today highlighted recent accomplishments across its diagnostic test programs and provided a preview of key business milestones it plans to achieve over the course of 2008. The Company also released financial results for the fourth quarter and year ended December 31, 2007.

"In 2007, Vermillion made significant clinical and commercial advancements in our diagnostic programs for peripheral artery disease (PAD), ovarian cancer and thrombotic thrombocytopenic purpura (TTP)," said Gail Page, President and CEO of Vermillion. "Our vision is to provide novel diagnostic tools to physicians in an effort to improve patient diagnosis and care. We continue to build awareness of the potential value proposition of our tests. Our primary focus will be on commercialization pathways in 2008."

Recent Accomplishments

Throughout the fourth quarter of 2007 and into the first quarter of 2008, Vermillion has advanced its PAD and ovarian cancer diagnostic programs, as well as accomplished numerous achievements at the corporate level:

PAD Diagnostic Test Progress

-- Completed a 540-patient clinical study evaluating the ability of

Vermillion's multi-marker panel to stratify individuals into high and

low risk groups for PAD. These results have been accepted for

publication in a peer-reviewed clinical journal and are expected to be

published in the first half of this year.

-- Entered into an exclusive license agreement with Stanford University to

develop and commercialize a biomarker panel used to assess the risk of

PAD. Under the terms of the agreeme
'/>"/>